| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $959,868 ) |
| | 2025 | 2025 | THERAPYX, INC. | 701 ELLICOTT ST | BUFFALO | NY | 14203-1101 | ERIE | USA | R44DK117687 | IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | 000 | 6 | NIH | 4/11/2025 | $959,868 |
|
| Issue Date FY: 2024 ( Subtotal = $1,960,296 ) |
| | 2024 | 2024 | THERAPYX, INC. | 701 ELLICOTT ST | BUFFALO | NY | 14203-1101 | ERIE | USA | SB1AI104067 | Therapy and Prophylaxis for Genital Tract Infection | 000 | 8 | NIH | 7/23/2024 | $1,000,000 |
| | 2024 | 2024 | THERAPYX, INC. | 701 ELLICOTT ST | BUFFALO | NY | 14203-1101 | ERIE | USA | R44DK117687 | IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | 000 | 5 | NIH | 3/25/2024 | $960,296 |
| | 2024 | 2022 | THERAPYX, INC. | 701 ELLICOTT ST | BUFFALO | NY | 14203-1101 | ERIE | USA | R44AI115877 | Experimental Gonococcal Vaccine | 000 | 6 | NIH | 3/25/2024 | $0 |
| | 2024 | 2022 | THERAPYX, INC. | 701 ELLICOTT ST | BUFFALO | NY | 14203-1101 | ERIE | USA | R44AI104067 | Therapy and Prophylaxis for Genital Tract Infection | 000 | 6 | NIH | 2/16/2024 | $0 |
| | 2024 | 2022 | THERAPYX, INC. | 701 ELLICOTT ST | BUFFALO | NY | 14203-1101 | ERIE | USA | R43AI170069 | OMV vaccine against Gonorrhea | 000 | 1 | NIH | 7/29/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,201,534 ) |
| | 2023 | 2023 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44DK117687 | IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | 001 | 4 | NIH | 5/31/2023 | $1,201,534 |
| | 2023 | 2023 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | SB1AI104067 | Therapy and Prophylaxis for Genital Tract Infection | 000 | 7 | NIH | 8/21/2023 | $1,000,000 |
| | 2023 | 2021 | THERAPYX, INC. | 2468 GRINSTEAD DRIVE | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44DK117687 | IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | 000 | 3 | NIH | 5/9/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,215,331 ) |
| | 2022 | 2022 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI115877 | Experimental Gonococcal Vaccine | 000 | 6 | NIH | 6/8/2022 | $1,000,000 |
| | 2022 | 2022 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI104067 | Therapy and Prophylaxis for Genital Tract Infection | 000 | 6 | NIH | 4/25/2022 | $915,331 |
| | 2022 | 2022 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R43AI170069 | OMV vaccine against Gonorrhea | 000 | 1 | NIH | 2/22/2022 | $300,000 |
| | 2022 | 2019 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44DK117687 | IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | 000 | 1 | NIH | 10/15/2021 | $0 |
| | 2022 | 2019 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R43AI147718 | Encapsulated anti-IL-10 for the immune therapy of gonorrhea infection | 001 | 1 | NIH | 2/10/2022 | $239,162 |
| | 2022 | 2019 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R43AI147718 | Encapsulated anti-IL-10 for the immune therapy of gonorrhea infection | 000 | 1 | NIH | 11/11/2021 | -$239,162 |
| | 2022 | 2019 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI080009 | Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD | 000 | 7 | NIH | 12/27/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,847,546 ) |
| | 2021 | 2021 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44DK117687 | IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | 000 | 3 | NIH | 3/8/2021 | $847,546 |
| | 2021 | 2021 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI115877 | Experimental Gonococcal Vaccine | 000 | 5 | NIH | 6/29/2021 | $1,000,000 |
| | 2021 | 2021 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI104067 | Therapy and Prophylaxis for Genital Tract Infection | 000 | 5 | NIH | 4/23/2021 | $1,000,000 |
| | 2021 | 2018 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R43AT009800 | PLGA encapsulated polyphenols to ameliorate IBD. | 000 | 1 | NIH | 10/19/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,665,530 ) |
| | 2020 | 2020 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI115877 | Experimental Gonococcal Vaccine | 001 | 4 | NIH | 7/15/2020 | $807,210 |
| | 2020 | 2020 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI104067 | Therapy and Prophylaxis for Genital Tract Infection | 000 | 4 | NIH | 5/1/2020 | $1,000,000 |
| | 2020 | 2020 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44DK117687 | IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | 000 | 2 | NIH | 2/27/2020 | $858,320 |
| | 2020 | 2018 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI115877 | Experimental Gonococcal Vaccine | 000 | 3 | NIH | 4/9/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,628,040 ) |
| | 2019 | 2019 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44DK117687 | IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | 000 | 1 | NIH | 3/7/2019 | $388,880 |
| | 2019 | 2019 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI080009 | Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD | 000 | 7 | NIH | 5/31/2019 | $999,998 |
| | 2019 | 2019 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R43AI147718 | Encapsulated anti-IL-10 for the immune therapy of gonorrhea infection | 000 | 1 | NIH | 7/31/2019 | $239,162 |
| | 2019 | 2016 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R43DK106938 | Oral sustained-release IL-10 microspheres for therapy of IBD | 000 | 1 | NIH | 11/14/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,308,788 ) |
| | 2018 | 2018 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R43AT009800 | PLGA encapsulated polyphenols to ameliorate IBD. | 000 | 1 | NIH | 6/8/2018 | $320,159 |
| | 2018 | 2018 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI080009 | Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD | 000 | 6 | NIH | 4/30/2018 | $999,998 |
| | 2018 | 2018 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI115877 | Experimental Gonococcal Vaccine | 000 | 3 | NIH | 1/5/2018 | $988,631 |
|
| Issue Date FY: 2017 ( Subtotal = $1,805,246 ) |
| | 2017 | 2017 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI115877 | Experimental Gonococcal Vaccine | 001 | 2 | NIH | 7/27/2017 | -$805,248 |
| | 2017 | 2017 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI080009 | Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD | 000 | 5 | NIH | 6/20/2017 | $999,998 |
| | 2017 | 2017 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI115877 | Experimental Gonococcal Vaccine | 001 | 2 | NIH | 7/27/2017 | $805,248 |
| | 2017 | 2017 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI115877 | Experimental Gonococcal Vaccine | 000 | 2 | NIH | 2/10/2017 | $805,248 |
| | 2017 | 2015 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R43AI115877 | Experimental Gonococcal Vaccine | 000 | 1 | NIH | 2/21/2017 | $0 |
| | 2017 | 2015 | THERAPYX,INC | 2468 GRINSTEAD DR | LOUISVILLE | KY | 40204-2304 | JEFFERSON | USA | R44AI104067 | Therapy and Prophylaxis for Genital Tract Infection | 000 | 3 | NIH | 6/5/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $295,831 ) |
| | 2016 | 2016 | THERAPYX INC | 138 FARBER HALL 3435 MAIN ST | BUFFALO | NY | 14214 | ERIE | USA | R43DK106938 | Oral sustained-release IL-10 microspheres for therapy of IBD | 000 | 1 | NIH | 9/2/2016 | $295,831 |
|
| Issue Date FY: 2015 ( Subtotal = $1,020,000 ) (Continued on the next page) |
| | 2015 | 2015 | THERAPYX INC | 138 FARBER HALL 3435 MAIN ST | BUFFALO | NY | 14214 | ERIE | USA | R44AI104067 | Therapy and Prophylaxis for Genital Tract Infection | 000 | 3 | NIH | 4/27/2015 | $749,000 |
|
